SCHEMBL24840982

SCHEMBL24840982

c1ccc(-c2nc(-c3ccccc3)nc(-c3ccc(-c4ccc(-c5ccc6oc7cccc(-c8nc(-c9ccccc9)nc(-c9ccccc9)n8)c7c6c5)cc4)cc3)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 4/20 0.43
PLA2G4A P47712 4/20 0.43
PLA2G10 O15496 1/20 0.41
PIM1 P11309 1/20 0.40
CSNK2A2 P19784 1/20 0.40
CSNK2B P67870 1/20 0.40
PIM3 Q86V86 1/20 0.40
PIM2 Q9P1W9 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
GAA P10253 1/20 0.40
PGR P06401 1/20 0.38
TBK1 Q9UHD2 1/20 0.38
ALDH1A1 P00352 4/20 0.37
HPGD P15428 4/20 0.37
MAPT P10636 3/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
TSHR P16473 2/20 0.37
ADORA3 P0DMS8 1/20 0.37
ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22884630 1.00 PLA2G2A (0.43) PLA2G2APLA2G4APLA2G10PIM1CSNK2A2
SCHEMBL23820082 1.00 PLA2G2A (0.43) PLA2G2APLA2G4APLA2G10PIM1CSNK2A2
SCHEMBL21152091 1.00 PLA2G2A (0.43) PLA2G2APLA2G4APLA2G10PIM1CSNK2A2
SCHEMBL22329343 1.00 PLA2G2A (0.43) PLA2G2APLA2G4APLA2G10PIM1CSNK2A2
SCHEMBL23138861 1.00 PLA2G2A (0.43) PLA2G2APLA2G4APLA2G10PIM1CSNK2A2
SCHEMBL23822619 1.00 PLA2G2A (0.43) PLA2G2APLA2G4APLA2G10PIM1CSNK2A2
SCHEMBL23821094 1.00 PLA2G2A (0.43) PLA2G2APLA2G4APLA2G10PIM1CSNK2A2
SCHEMBL23820239 1.00 PLA2G2A (0.43) PLA2G2APLA2G4APLA2G10PIM1CSNK2A2
SCHEMBL21741714 1.00 PLA2G2A (0.43) PLA2G2APLA2G4APLA2G10PIM1CSNK2A2
SCHEMBL22884383 1.00 PLA2G2A (0.43) PLA2G2APLA2G4APLA2G10PIM1CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228523-A1 Metal complexes UDC IRELAND LTD (IE) 2024-07-11 US disclosed
US-20240228523-A1 Metal complexes UDC IRELAND LTD (IE) 2024-07-11 US disclosed
WO-2024033282-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2024-02-15 WO disclosed
US-20230331754-A1 MONONUCLEAR TRIPODAL HEXADENTATE IRIDIUM COMPLEXES FOR USE IN OLEDS UDC IRELAND LIMITED (IE) 2023-10-19 US disclosed
US-20230331754-A1 MONONUCLEAR TRIPODAL HEXADENTATE IRIDIUM COMPLEXES FOR USE IN OLEDS UDC IRELAND LIMITED (IE) 2023-10-19 US disclosed
US-20230295104-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2023-09-21 US disclosed
US-20230295104-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2023-09-21 US disclosed
US-20230006143-A1 MIXTURE OF TWO HOST MATERIALS, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME MERCK PATENT GMBH (DE) 2023-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331754-A1 MONONUCLEAR TRIPODAL HEXADENTATE IRIDIUM COMPLEXES FOR USE IN OLEDS OCIAD1, OCIAD2, NUDT1 PLA2G2A 2493/4885PLA2G4A 1717/4885PLA2G10 2258/4885
US-20240228523-A1 Metal complexes MCU, IMMT, SOD1 PLA2G2A 4016/4885PLA2G4A 4418/4885PLA2G10 4442/4885
US-20230295104-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES OR10J3, L1CAM, EPCAM PLA2G2A 3935/4885PLA2G4A 4499/4885PLA2G10 4373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.